Weiter zum Inhalt

What Innovative Pharmaceutical Research is Protected under the SPC-Regime? A Discussion of the ECJ's Decision in the Abraxis Case

Otto Swens, Carly van der Beek

DOI https://doi.org/10.21552/eplr/2019/2/8



Otto Swens and Carly van der Beek work as attorneys at Vondst Advocaten, Amsterdam. For correspondence: <mailto:otto.swens@vondst.com> <mailto:carly.vanderbeek@vondst.com>.

Empfehlen


Lx-Nummer Suche

A
|
(z.B.: A | 000123 | 01)

Quelle speichern